- To establish whether a reduced dose of rivaroxaban significantly decreased the composite outcome in patients on hemodialysis with atrial fibrillation.
- To determine clinical significance of study results.
Friday, May 21, 2021 - 12:00pm to 1:00pm
5700 S Maryland Ave
Chicago, IL 60637
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Anand Narayanan, MD